| Owen Biosciences Inc. | D-0452-2026 | Chemical contamination: Presence of benzene | Class II | 2026-03-03 |
|---|
| Owen Biosciences Inc. | D-0454-2026 | Chemical contamination: Presence of benzene | Class II | 2026-03-03 |
|---|
| Owen Biosciences Inc. | D-0455-2026 | Chemical contamination: Presence of benzene | Class II | 2026-03-03 |
|---|
| Owen Biosciences Inc. | D-0453-2026 | Chemical contamination: Presence of benzene | Class II | 2026-03-03 |
|---|
| Private Label Skin Care Inc. | D-0668-2025 | Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products. | Class II | 2025-09-12 |
|---|
| Private Label Skin Care Inc. | D-0663-2025 | Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products. | Class II | 2025-09-12 |
|---|
| Private Label Skin Care Inc. | D-0666-2025 | Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products. | Class II | 2025-09-12 |
|---|
| Private Label Skin Care Inc. | D-0667-2025 | Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products. | Class II | 2025-09-12 |
|---|
| Private Label Skin Care Inc. | D-0664-2025 | Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products. | Class II | 2025-09-12 |
|---|
| Private Label Skin Care Inc. | D-0665-2025 | Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products. | Class II | 2025-09-12 |
|---|
| American Contract Systems Inc. | Z-0180-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0185-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0174-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0173-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0187-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0170-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0184-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0171-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0186-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0182-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0175-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0181-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0172-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0176-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0183-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0178-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0177-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems Inc. | Z-0179-2026 | Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed. | Class II | 2025-09-04 |
|---|
| American Contract Systems, Inc. | Z-1916-2025 | Test results for cast padding component included in procedure trays shows Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals exceeded residual limits, which may lead to a possible loss or lack of functionality that may lead to a delay or prolonged treatment/procedure/therapy. | Class II | 2025-04-21 |
|---|
| Alchemee, LLC | D-0360-2025 | Chemical contamination: Presence of benzene | Class II | 2025-03-12 |
|---|
| Alchemee, LLC | D-0359-2025 | Chemical contamination: Presence of benzene | Class II | 2025-03-12 |
|---|
| Fruit Of The Earth, Inc. | D-0284-2025 | Chemical contamination: presence of benzene | Class II | 2025-03-11 |
|---|
| Fruit Of The Earth, Inc. | D-0283-2025 | Chemical contamination: presence of benzene | Class II | 2025-03-11 |
|---|
| L'Oreal USA | D-0419-2025 | cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution, the firm voluntarily recalled all La Roche-Posay Effaclar Duo Dual Action Acne Treatment lots. | Class II | 2025-03-05 |
|---|
| L'Oreal USA | D-0418-2025 | cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution, the firm voluntarily recalled all La Roche-Posay Effaclar Duo Dual Action Acne Treatment lots. | Class II | 2025-03-05 |
|---|
| L'Oreal USA | D-0417-2025 | Chemical Contamination: This recall has been initiated due to detected trace levels of benzene. | Class II | 2025-03-05 |
|---|
| Strides Pharma, Inc. | D-0294-2025 | Presence of foreign substance: Presence of Benzene. | Class II | 2025-03-05 |
|---|
| Strides Pharma, Inc. | D-0293-2025 | Presence of foreign substance: Presence of Benzene. | Class II | 2025-03-05 |
|---|
| Sigan Industries Group Inc. | D-0274-2025 | Chemical Contamination: Presence of benzene | Class II | 2025-02-28 |
|---|
| Denison Pharmaceuticals, LLC | D-0273-2025 | Chemical Contamination: Presence of benzene. | Class II | 2025-02-24 |
|---|
| American Contract Systems Inc | Z-2275-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2288-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2310-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2280-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2281-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2305-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2311-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2301-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2292-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2279-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2300-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2287-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2293-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2290-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2283-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2286-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2274-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2278-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2308-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2294-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2297-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2284-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2303-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2282-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2306-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2302-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2291-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2276-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2309-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2307-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2296-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2285-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2299-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2277-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2304-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2312-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2289-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2295-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| American Contract Systems Inc | Z-2298-2024 | Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012. | Class II | 2024-05-15 |
|---|
| Covidien | Z-1330-2024 | Packs including 5 laparotomy sponges may contain incorrect product with a blue loop, X-ray detectable feature, and ethylene oxide treatment; however, this incorrect product wasn't steam pre-treated prior to sterilization, and has no RF tag, which if non-sterile, may lead to infection, tissue trauma, and sepsis, and if in the scannable area, would lead a "CLEAR" display. | Class II | 2024-02-21 |
|---|
| Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare company | D-0346-2024 | Chemical Contamination; presence of benzene. | Class I | 2024-02-01 |
|---|
| Covidien, LP | Z-1697-2024 | One lot of product was exposed to more than the approved number of Ethylene Oxide (EO) sterilization cycles. This may decrease the tensile strength of the sutures over time, which could result in harms such as wound dehiscence, hemorrhage, blood loss, bleeding, tissue breakdown, peritonitis, unspecified infection, vision loss (when used in ophthalmic application), and/or prolonged surgery. | Class II | 2024-01-25 |
|---|
| Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare company | D-0236-2024 | Chemical Contamination: presence of benzene | Class I | 2023-12-21 |
|---|
| Insight Pharmaceuticals Corporation | D-0151-2024 | Chemical Contamination; presence of benzene. | Class I | 2023-11-22 |
|---|
| Teva Pharmaceuticals USA Inc | D-0441-2023 | CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. | Class II | 2023-02-22 |
|---|
| Steris Corporation | Z-0781-2023 | Biological indicator (BI) used to promote growth of the G. stearothermophilus and B. atrophaeus spores was inconsistent in promoting growth throughout lot , some BIs within the lot performed as intended while others did not. When used to monitor steam and ethylene oxide sterilization cycles, the potential hazard is that the BI will show no growth indicating that the cycle was effective, even if it | Class II | 2022-12-12 |
|---|
| Steris Corporation | Z-0779-2023 | Biological indicator (BI) used to promote growth of the G. stearothermophilus and B. atrophaeus spores was inconsistent in promoting growth throughout lot , some BIs within the lot performed as intended while others did not. When used to monitor steam and ethylene oxide sterilization cycles, the potential hazard is that the BI will show no growth indicating that the cycle was effective, even if it | Class II | 2022-12-12 |
|---|
| Steris Corporation | Z-0780-2023 | Biological indicator (BI) used to promote growth of the G. stearothermophilus and B. atrophaeus spores was inconsistent in promoting growth throughout lot , some BIs within the lot performed as intended while others did not. When used to monitor steam and ethylene oxide sterilization cycles, the potential hazard is that the BI will show no growth indicating that the cycle was effective, even if it | Class II | 2022-12-12 |
|---|
| Steris Corporation | Z-0778-2023 | Biological indicator (BI) used to promote growth of the G. stearothermophilus and B. atrophaeus spores was inconsistent in promoting growth throughout lot , some BIs within the lot performed as intended while others did not. When used to monitor steam and ethylene oxide sterilization cycles, the potential hazard is that the BI will show no growth indicating that the cycle was effective, even if it | Class II | 2022-12-12 |
|---|
| Salon Technologies International Inc | D-0002-2023 | Chemical Contamination: product found to contain benzene | Class I | 2022-09-14 |
|---|
| Edgewell Personal Care Brands, LLC | D-0212-2024 | Chemical contamination: presence of benzene | Class I | 2022-07-29 |
|---|
| Crown Prince, Inc | F-1551-2022 | Detectable levels of Per- and polyfluoroalkyl substances (PFAS). | Class II | 2022-07-15 |
|---|
| Bumble Bee Foods, LLC | F-1508-2022 | Detectable levels of Per- and polyfluoroalkyl substances (PFAS). | Class II | 2022-07-06 |
|---|
| Unilever United States Inc. | D-0210-2024 | Chemical contamination: presence of benzene | Class I | 2022-03-30 |
|---|
| Unilever United States Inc. | D-0211-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2022-03-30 |
|---|
| Best Brands Consumer Products, Inc. | D-0877-2022 | Chemical Contamination; FDA analysis found product to contain benzene | Class I | 2022-03-29 |
|---|
| TCP HRB ACQUISITON LLC | D-0208-2024 | Chemical contamination: Presence of benzene | Class I | 2022-02-16 |
|---|
| TCP HRB ACQUISITON LLC | D-0207-2024 | Chemical contamination: Presence of benzene | Class I | 2022-02-16 |
|---|
| TCP HRB ACQUISITON LLC | D-0209-2024 | Chemical contamination: Presence of benzene | Class I | 2022-02-16 |
|---|
| RemedyRepack Inc. | D-0366-2022 | CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. | Class II | 2021-12-30 |
|---|
| VIONA PHARMACEUTICALS INC | D-0392-2022 | CGMP Deviations- Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. | Class II | 2021-12-27 |
|---|
| The Procter & Gamble Company | D-0248-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0249-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0242-2024 | Chemical contamination: presence of benzene | Class I | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0247-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0252-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0251-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0253-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0244-2024 | Chemical contamination: presence of benzene | Class I | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0238-2024 | Chemical contamination: presence of benzene | Class I | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0239-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0246-2024 | Chemical contamination: presence of benzene | Class I | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0256-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0254-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0250-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0241-2024 | Chemical contamination: presence of benzene | Class I | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0240-2024 | Chemical contamination: presence of benzene | Class I | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0243-2024 | Chemical contamination: presence of benzene | Class I | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0255-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| The Procter & Gamble Company | D-0245-2024 | CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzene | Class II | 2021-11-23 |
|---|
| Blistex Inc | D-0159-2024 | Chemical contamination: Presence of benzene | Class I | 2021-11-17 |
|---|
| VIRGIN SCENT INC | D-0782-2022 | Chemical Contamination: presence of benzene, acetaldehyde, and acetal. | Class I | 2021-10-26 |
|---|
| Karl Storz Endoscopy | Z-0442-2022 | To ensure sterilization effectiveness, sterilization tray instructions for use were updated and now state 1) udel trays may be used with flexible endoscopes with lumen diameters greater-than-or-equal to 1.2mm and maximum length of 845mm and 2) ethylene oxide is excluded as a sterilization modality. | Class II | 2021-10-15 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0253-2022 | Chemical Contamination: presence of benzene | Class I | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0251-2022 | Chemical Contamination: presence of benzene | Class I | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0242-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0247-2022 | Chemical Contamination: presence of benzene | Class I | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0236-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0249-2022 | Chemical Contamination: presence of benzene | Class I | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0239-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0246-2022 | Chemical Contamination: presence of benzene | Class I | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0240-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0250-2022 | Chemical Contamination: presence of benzene | Class I | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0237-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0254-2022 | cGMP Deviations: LOTRIMIN AF (Tolnaftate 1%) manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0243-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0252-2022 | Chemical Contamination: presence of benzene | Class I | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0238-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0241-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0245-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0244-2022 | cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. | Class II | 2021-10-01 |
|---|
| Bayer Healthcare Pharmaceuticals Inc. | D-0248-2022 | Chemical Contamination: presence of benzene | Class I | 2021-10-01 |
|---|
| Beiersdorf Inc | D-0013-2022 | Chemical contamination; presence of benzene | Class I | 2021-09-30 |
|---|
| Beiersdorf Inc | D-0011-2022 | Chemical contamination; presence of benzene | Class I | 2021-09-30 |
|---|
| Beiersdorf Inc | D-0014-2022 | Chemical contamination; presence of benzene | Class I | 2021-09-30 |
|---|
| Beiersdorf Inc | D-0012-2022 | Chemical contamination; presence of benzene | Class I | 2021-09-30 |
|---|
| Beiersdorf Inc | D-0010-2022 | Chemical contamination; presence of benzene | Class I | 2021-09-30 |
|---|
| Johnson & Johnson Consumer, Inc. | D-0844-2021 | Chemical Contamination: presence of benzene | Class I | 2021-07-14 |
|---|
| Johnson & Johnson Consumer, Inc. | D-0845-2021 | Chemical Contamination: presence of benzene | Class I | 2021-07-14 |
|---|
| VIONA PHARMACEUTICALS INC | D-0640-2021 | CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. | Class II | 2021-06-01 |
|---|
| Covidien, LP | Z-1868-2021 | The company was notified by their supplier of sterilization services for airway products in Italy of potential deviations from validated parameters for ethylene oxide sterilization. | Class II | 2021-04-29 |
|---|
| Covidien, LP | Z-1867-2021 | The company was notified by their supplier of sterilization services for airway products in Italy of potential deviations from validated parameters for ethylene oxide sterilization. | Class II | 2021-04-29 |
|---|
| Covidien, LP | Z-1866-2021 | The company was notified by their supplier of sterilization services for airway products in Italy of potential deviations from validated parameters for ethylene oxide sterilization. | Class II | 2021-04-29 |
|---|
| Covidien, LP | Z-1869-2021 | The company was notified by their supplier of sterilization services for airway products in Italy of potential deviations from validated parameters for ethylene oxide sterilization. | Class II | 2021-04-29 |
|---|
| Preferred Pharmaceuticals, Inc. | D-0385-2021 | CMGP Deviations: Presence of NDMA impurity detected in product and exceed the Acceptable Daily Intake Limit (ADI) of 96ng/day. | Class II | 2021-04-28 |
|---|
| Scentsational Soaps & Candles Inc | D-0682-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0677-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0673-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0668-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0678-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0666-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0671-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0672-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0681-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0670-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0679-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0676-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0674-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0675-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0680-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0684-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0683-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0669-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Scentsational Soaps & Candles Inc | D-0667-2021 | Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde. | Class I | 2021-04-27 |
|---|
| Spes Medica | Z-1968-2021 | The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization. | Class II | 2021-04-08 |
|---|
| Spes Medica | Z-1967-2021 | The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization. | Class II | 2021-04-08 |
|---|
| Spes Medica | Z-1971-2021 | The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization. | Class II | 2021-04-08 |
|---|
| Spes Medica | Z-1970-2021 | The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization. | Class II | 2021-04-08 |
|---|
| Spes Medica | Z-1969-2021 | The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization. | Class II | 2021-04-08 |
|---|
| Covidien Llc | Z-1419-2021 | Potential for the pouch to contain an extra laminate layer, creating the potential for the device sterility to be compromised. The inclusion of an additional laminate layer in the package may also impact complete de-gassing of the sterilization gas, Ethylene Oxide and may result in a potentially increased risk for patient infection and/or potential exposure to Ethylene Oxide retained in the pouch | Class II | 2021-03-23 |
|---|
| Nostrum Laboratories Inc | D-0249-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level. | Class II | 2021-01-25 |
|---|
| Nostrum Laboratories Inc | D-0227-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2021-01-04 |
|---|
| Preferred Pharmaceuticals, Inc. | D-0077-2021 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. | Class II | 2020-11-01 |
|---|
| Nostrum Laboratories Inc | D-0068-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-10-23 |
|---|
| Nostrum Laboratories Inc | D-0067-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-10-23 |
|---|
| Direct Rx | D-0058-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer) | Class II | 2020-10-12 |
|---|
| RemedyRepack Inc. | D-0050-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer) | Class II | 2020-10-11 |
|---|
| Denton Pharma, Inc. | D-0057-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer) | Class II | 2020-10-08 |
|---|
| Denton Pharma, Inc. | D-0056-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer) | Class II | 2020-10-08 |
|---|
| PD-Rx Pharmaceuticals, Inc. | D-0060-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer) | Class II | 2020-10-06 |
|---|
| PD-Rx Pharmaceuticals, Inc. | D-0059-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer) | Class II | 2020-10-06 |
|---|
| Marksans Pharma Limited | D-0061-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-10-02 |
|---|
| Marksans Pharma Limited | D-0062-2021 | CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-10-02 |
|---|
| SUN PHARMACEUTICAL INDUSTRIES INC | D-0002-2021 | CGMP Deviations: Detection of N-nitrosodimethylamine (NDMA) impurity in finished drug product. | Class II | 2020-09-23 |
|---|
| Karl Storz Endoscopy | Z-2892-2020 | Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection. | Class II | 2020-07-27 |
|---|
| Karl Storz Endoscopy | Z-2895-2020 | Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection. | Class II | 2020-07-27 |
|---|
| Karl Storz Endoscopy | Z-2890-2020 | Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection. | Class II | 2020-07-27 |
|---|
| Karl Storz Endoscopy | Z-2893-2020 | Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection. | Class II | 2020-07-27 |
|---|
| Karl Storz Endoscopy | Z-2897-2020 | Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection. | Class II | 2020-07-27 |
|---|
| Karl Storz Endoscopy | Z-2896-2020 | Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection. | Class II | 2020-07-27 |
|---|
| Karl Storz Endoscopy | Z-2894-2020 | Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection. | Class II | 2020-07-27 |
|---|
| Karl Storz Endoscopy | Z-2891-2020 | Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection. | Class II | 2020-07-27 |
|---|
| Lupin Pharmaceuticals Inc. | D-1382-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-07-07 |
|---|
| Lupin Pharmaceuticals Inc. | D-1385-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-07-07 |
|---|
| Lupin Pharmaceuticals Inc. | D-1384-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-07-07 |
|---|
| Lupin Pharmaceuticals Inc. | D-1383-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-07-07 |
|---|
| Granules Pharmaceuticals Inc | D-1386-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-07-03 |
|---|
| Sutter Medizintechnik GmbH | Z-2744-2020 | The label on the cardbox and the blister show the correct symbols for sterilization using irradiation and storage at 5 C to 40 C, the package insert (IFU) is labelled incorrectly. It shows the symbol for sterilization using Ethylene Oxide with the description for sterilization using irradiation. | Class II | 2020-06-23 |
|---|
| Preferred Pharmaceuticals, Inc. | D-1364-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. | Class II | 2020-06-17 |
|---|
| The Harvard Drug Group | D-1360-2020 | CGMP Deviation: Potential presence of Nitrosodimethylamine (NDMA) Impurity above the established levels. | Class II | 2020-06-12 |
|---|
| Lupin Pharmaceuticals Inc. | D-1334-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-06-11 |
|---|
| Marksans Pharma Limited | D-1356-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-06-05 |
|---|
| PD-Rx Pharmaceuticals, Inc. | D-1333-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-06-05 |
|---|
| PD-Rx Pharmaceuticals, Inc. | D-1307-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-06-05 |
|---|
| AVKARE Inc. | D-1305-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-06-04 |
|---|
| AVKARE Inc. | D-1304-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-06-04 |
|---|
| Teva Pharmaceuticals USA | D-1331-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-06-02 |
|---|
| Teva Pharmaceuticals USA | D-1332-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-06-02 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1349-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1348-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1351-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1354-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1350-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1352-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1353-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1344-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1393-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1347-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1343-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1345-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level | Class II | 2020-05-29 |
|---|
| Apotex Inc. | D-1303-2020 | CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levels | Class II | 2020-05-27 |
|---|
| Amneal Pharmaceuticals of New York, LLC | D-1253-2020 | CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA. | Class II | 2020-04-15 |
|---|
| Direct Rx | D-0017-2021 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2020-01-15 |
|---|
| Direct Rx | D-0016-2021 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2020-01-15 |
|---|
| Spectrum Laboratory Products | D-0825-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2020-01-14 |
|---|
| PD-Rx Pharmaceuticals, Inc. | D-0826-2020 | CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels. | Class II | 2020-01-10 |
|---|
| Mylan Pharmaceuticals Inc. | D-0791-2020 | CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine. | Class II | 2020-01-07 |
|---|
| Mylan Pharmaceuticals Inc. | D-0792-2020 | CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine. | Class II | 2020-01-07 |
|---|
| Preferred Pharmaceuticals, Inc | D-0797-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2020-01-07 |
|---|
| Preferred Pharmaceuticals, Inc | D-0796-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2020-01-07 |
|---|
| Appco Pharma LLC | D-0648-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2020-01-07 |
|---|
| Appco Pharma LLC | D-0649-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2020-01-07 |
|---|
| H J Harkins Company Inc dba Pharma Pac | D-0793-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2020-01-06 |
|---|
| AAA Pharmaceutical, Inc. | D-0645-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-12-26 |
|---|
| AAA Pharmaceutical, Inc. | D-0646-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-12-26 |
|---|
| Denton Pharma, Inc. | D-0794-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-20 |
|---|
| Denton Pharma, Inc. | D-0795-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-20 |
|---|
| Glenmark Pharmaceuticals Inc., USA | D-0643-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-17 |
|---|
| Glenmark Pharmaceuticals Inc., USA | D-0642-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-17 |
|---|
| Glenmark Pharmaceuticals Inc., USA | D-0639-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-17 |
|---|
| Glenmark Pharmaceuticals Inc., USA | D-0644-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-17 |
|---|
| Glenmark Pharmaceuticals Inc., USA | D-0640-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-17 |
|---|
| Glenmark Pharmaceuticals Inc., USA | D-0641-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-17 |
|---|
| Granules India Limited | D-0632-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-12-13 |
|---|
| RemedyRepack Inc. | D-0798-2020 | CGMP Deviation; Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels. | Class II | 2019-12-11 |
|---|
| Preferred Pharmaceuticals, Inc | D-0617-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-12-02 |
|---|
| Amneal Pharmaceuticals, Inc. | D-0613-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-11-22 |
|---|
| Amneal Pharmaceuticals, Inc. | D-0616-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-11-22 |
|---|
| Amneal Pharmaceuticals, Inc. | D-0612-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-11-22 |
|---|
| Amneal Pharmaceuticals, Inc. | D-0615-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-11-22 |
|---|
| Amneal Pharmaceuticals, Inc. | D-0614-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-11-22 |
|---|
| American Health Packaging | D-1003-2020 | CGMP Deviations: Potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA. | Class II | 2019-11-20 |
|---|
| AVKARE Inc. | D-0524-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-11-14 |
|---|
| AVKARE Inc. | D-0525-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | 2019-11-14 |
|---|
| Precision Dose Inc. | D-1004-2020 | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API. | Class II | 2019-11-13 |
|---|
| AuroMedics Pharma LLC | D-0529-2020 | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups. | Class II | 2019-11-06 |
|---|
| AuroMedics Pharma LLC | D-0528-2020 | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups. | Class II | 2019-11-06 |
|---|
| AuroMedics Pharma LLC | D-0527-2020 | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups. | Class II | 2019-11-06 |
|---|
| AuroMedics Pharma LLC | D-0530-2020 | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups. | Class II | 2019-11-06 |
|---|
| AuroMedics Pharma LLC | D-0526-2020 | CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups. | Class II | 2019-11-06 |
|---|
| American Health Packaging | D-0631-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-11-01 |
|---|
| Novitium Pharma LLC | D-0311-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-25 |
|---|
| Sanofi-Aventis U.S. LLC | D-0534-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0540-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0542-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0544-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0535-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0536-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0539-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0538-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0543-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0541-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0545-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Sanofi-Aventis U.S. LLC | D-0537-2020 | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II | 2019-10-22 |
|---|
| Maquet Cardiovascular, LLC | Z-1640-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1506-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1638-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1509-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1564-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1651-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1591-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1587-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1663-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1532-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1643-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1585-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1672-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1659-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Maquet Cardiovascular, LLC | Z-1656-2019 | Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assured | Class II | 2019-04-18 |
|---|
| Ecolab Inc | D-1064-2019 | Chemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor. | Class II | 2019-02-06 |
|---|
| Ecolab Inc | D-1062-2019 | Chemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor. | Class II | 2019-02-06 |
|---|
| Karl Storz Endoscopy | Z-1942-2020 | The sterile single-use tubing may contain higher ethylene oxide (EO) residues than the acceptable level. | Class III | 2019-01-09 |
|---|